Altimmune announces second quarter 2023 financial results and provides a business update

Top-line 48-week results from the momentum phase 2 obesity trial expected q4 2023 commenced enrollment in impact phase 2b trial of pemvidutide in non-alcoholic steatohepatitis (nash) top-line results from the phase 2 trial of heptcell™ in chronic hepatitis b (chb) expected q1 2024 webcast to be held today, august 10, 2023, at 8:30 am edt gaithersburg, md., aug. 10, 2023 (globe newswire) -- altimmune, inc. (nasdaq: alt), a clinical-stage biopharmaceutical company, today announced financial results for the three months ended june 30, 2023, and provided a business update.
ALT Ratings Summary
ALT Quant Ranking